Sar-OBzl*TFA

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Sar-OBzl*TFA
• 英文别名: Sar-OBzl trifluoroacetate；benzyl (methylamino)acetate trifluoroacetate；benzyl methylglycinate trifluoroacetate；benzyl N-methylglycinate trifluoroacetic acid salt；benzyl 2-(methylamino)acetate trifluoroacetic acid salt；Methyl-(2-oxo-2-phenylmethoxyethyl)azanium;2,2,2-trifluoroacetate
• 化学式: C₂HF₃O₂*C₁₀H₁₃NO₂
• 分子量: 293.243
• InChiKey: JWMICYOLIVXBKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.78
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  83
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Sar-OBzl*TFA 在 sodium hydride 、 碳酸氢钠 作用下， 以 二氯甲烷 、 N,N-二甲基乙酰胺 、 mineral oil 为溶剂， 反应 16.17h， 生成 1-[N-(2-benzyloxy-2-oxoethyl)-N-methylcarbamoyl]-5-fluorouracil
  参考文献：
  名称：

  Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs

  摘要：

  In order to identify new efficient prodrugs of 5-fluorouracil (5-FU) and to develop an original targeting approach using 2-fluoro-2-deoxyglucose (FDG) as a potential drug carrier, eight original 5-FU derivatives were synthesized: 5-FU was attached by the N1 position of the pyrimidinic ring to the C1 position of the FDG structure either by direct coupling (2a) or via various spacers (3, 6a-c, 10b and 19). A new sensitive high-performance liquid chromatography method was developed to simultaneously quantify 5-FU and its derivatives in human plasma and other relevant media at physiological temperatures. Half-lives were determined from the degradation profiles of these conjugates. Slow degradation of compounds 2a, 3, 10b and 19 was observed in vitro at 37 degrees C, but no 5-FU release was noticed. By contrast, the in vitro drug release profiles of compounds 6a-c followed pseudo-first-order kinetics, and 5-FU was found in all the media. The antiproliferative activity of the eight compounds was assessed in vitro by a fluorometric assay against two human solid cancer cell lines and one healthy cell line. A correlation was found between the activities of the compounds and their ability to release 5-FU efficiently. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.04.010
• 作为产物：
  描述：

  叔丁氧羰基氨基-乙酸苄酯 在 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 、 mineral oil 为溶剂， 反应 5.5h， 生成 Sar-OBzl*TFA
  参考文献：
  名称：

  从手性高级环氧化物全合成 (–)-negamycin

  摘要：

  摘要 描述了 (–)-negamycin 全合成的简明路线。关键点特征 (a) 铜介导的高级环氧化物与乙烯基氯化镁的开环反应导致羧基合成子的引入；(b) 设计了通过叠氮化物连续放置二氨基，包括甲硅烷基保护基的意外裂解；(c) 一步去除四个氢解不稳定基团。

  DOI：

  10.1080/00397911.2022.2153339

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR ADMINISTRATION OCULAIRE
  申请人：GRAYBUG VISION INC

  公开号：WO2020069353A1

  公开（公告）日：2020-04-02

  The present invention provides new prodrags of Sunitinib, Brinzolamide, and Dorzolamide and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (TOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

  本发明提供了新的Sunitinib、Brinzolamide和Dorzolamide的前药，以及用于治疗医学疾病的组合物，例如青光眼、与眼内压增高有关的疾病或异常（TOP）、需要神经保护的疾病、年龄相关性黄斑变性或糖尿病视网膜病变。
• [EN] DRUGS TO TREAT OCULAR DISORDERS<br/>[FR] MÉDICAMENTS POUR TRAITER DES TROUBLES OCULAIRES
  申请人：GRAYBUG VISION INC

  公开号：WO2019210215A1

  公开（公告）日：2019-10-31

  The present invention provides new prodrugs of therapeutically active loop diuretics, including oligomeric prodrugs, and compositions to treat medical disorders, for example, ocular disorders such as glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

  本发明提供了治疗活性环利尿剂的新前药，包括寡聚前药，以及用于治疗医学疾病的组合物，例如眼部疾病，如青光眼，与眼内压增高相关的疾病或异常，需要神经保护的疾病，年龄相关性黄斑变性或糖尿病视网膜病变。
• Highly Efficient Synthesis of Sterically Hindered Peptides Containing N-Methylated Amino Acid Residues using a Novel 1H-Benzimidazolium Salt
  作者：Peng Li、Jie Cheng Xu

  DOI：10.1016/s0040-4020(00)00963-7

  日期：2000.12

  Novel 1H-benzimidazolium type peptide coupling reagent, CMBI, was designed, synthesized, and shown to be efficient in the promotion of the formation of sterically hindered amide and ester bonds. Its high efficiency was proved by model reaction tests and the successful synthesis of various hindered oligopeptides and peptide segments containing N-methyl amino acid residues with fast reaction speeds, low

  设计，合成了新型1 H-苯并咪唑型肽偶联剂CMBI，证明其在促进空间位阻酰胺和酯键形成方面是有效的。通过模型反应试验和成功合成了各种受阻寡肽和含有N-甲基氨基酸残基的肽段，证明了其高效率，其反应速度快，外消旋化程度低且产率高。提出了由试剂介导的酰胺键形成机理。
• WO2020109792A5
  申请人：——

  公开号：WO2020109792A5

  公开（公告）日：2022-11-09
• Total Synthesis of Cyclosporin O Both in Solution and in the Solid Phase Using Novel Thiazolium-, Immonium-, and Pyridinium-Type Coupling Reagents:  BEMT, BDMP, and BEP¹
  作者：Peng Li、Jie Cheng Xu

  DOI：10.1021/jo991687c

  日期：2000.5.1

  Cyclosporin O (1), an extensively N-methylated immunosuppressive cyclic undecapeptide isolated from Tolypocladium inflatum Gams, was synthesized in 20-23% overall yield via 4 + 7 segment condensation and cyclization by the combined utilization of novel thiazolium- and immonium-type peptide coupling reagents 2-bromo-3-ethyl-4-methyl thiazolium tetrafluoroborate (BEMT) and 5-(1H-benzotriazol-1-yloxy)-3,4-dihydro-1-methyl 2H-pyrrolium hexachloroantimonate (BDMP) as well as compound 2-bromo-1-ethyl pyridinium tetrafluoroborate (BEP). BEMT and BEP, which have been proven to be very efficient for the coupling of peptide segments containing N-alkylated amino acid residues with respect to the fast reaction speed, low racemization, and high yields, were used to construct hindered amide bonds in CsO with the addition of HOAt, whereas the most efficient HOBt-derived immonium type reagent, BDMP, was used to perform the coupling of coded amino acids in CsO. Thus, the highly hindered protected 8-11 tetrapeptide 25 was successfully synthesized using BEMT in 65% yield, and the 1-7 heptapeptide 21 was obtained in 52-55% yield by the rationally combined utilization of BDMP, BEMT, and BEP. The synthesis of the linear undecapeptide 27 of CsO in the solid phase using BEMT and BEP was accomplished for the further evaluation of the effectiveness of these reagents.